Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications.
about
Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistanceDiabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesSpatiotemporal control over growth factor signaling for therapeutic neovascularizationVasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformationPeripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expressionVascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb modelPhysiology of in-situ arterial revascularization in coronary artery bypass grafting: Preoperative, intraoperative and postoperative factors and influencesCollaterals that regressed after angioplasty can be recruited to protect the left ventricle in case of an acute occlusionCLIC5 mutant mice are resistant to diet-induced obesity and exhibit gastric hemorrhaging and increased susceptibility to torporDistinct kinin-induced functions are altered in circulating cells of young type 1 diabetic patientsPlasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease.Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy.Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic miceGeneration of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic miceCoadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats.Cancer biology in diabetes.Amphiphilic degradable polymers for immobilization and sustained delivery of sphingosine 1-phosphate.Diabetic monocyte and vascular endothelial growth factor signaling impairment.Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states.Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetesERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish.High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism.Adiponectin actions in the cardiovascular system.Modulating Notch signaling to enhance neovascularization and reperfusion in diabetic mice.Beneficial effects of ginsenoside-Rg1 on ischemia-induced angiogenesis in diabetic mice.Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus.Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemiaAngiopoietin/Tie2 pathway mediates type 2 diabetes induced vascular damage after cerebral strokeSecretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization.Characterization of the genomic structure and function of regions influencing renin and angiogenesis in the SS rat.Improved diabetic wound healing through topical silencing of p53 is associated with augmented vasculogenic mediatorsCo-transplantation of endothelial progenitor cells and pancreatic islets to induce long-lasting normoglycemia in streptozotocin-treated diabetic rats.Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells.MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK.Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress.High cortisol levels are associated with low quality food choice in type 2 diabetes.Manipulating angiogenesis in medicine.Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia.Modeling chick to assess diabetes pathogenesis and treatment.
P2860
Q24306665-4F325945-F91A-4A03-A1DA-E92C5876B13BQ24608301-68B9172F-D22C-41E4-9A68-2160691E1332Q24641819-1439B71E-8731-4B4F-BD5E-997B7B791D5DQ24799326-7DB26B49-E639-4F5D-B245-42730CE06070Q24805783-A5E4FB88-FDDD-445B-9578-8C373B52B96EQ24807288-3ACE8FED-F573-4612-B80B-B36F6ABAC0FEQ28071493-C0BB3A25-8436-4782-A86D-E1760EA40D08Q28192262-EA5B82A8-B2A8-486A-B98C-1317F837B6D9Q28512655-E566FA3D-2499-4253-BE7F-790148DF6F93Q28751480-839AE3FA-D53C-4B39-B509-CB2835CEF133Q30431716-D601CD58-9BAF-4A54-AF84-C62FA6CB52D1Q30433579-0394011D-25A8-4D50-8774-AE3369BA79DDQ30503408-74EDB277-4496-41F0-A733-BF1208A5B66BQ30542133-5EDEEFDE-E26F-45EB-B4CC-A8B2AEE32B15Q31146191-65A3A4B2-012C-47EA-91BE-3C3FE16BDE01Q33556657-983DCA70-A542-4608-8CF2-024A9A17D2CCQ33608038-F4EFE3F8-29C6-49D8-B44D-12C7D107FACFQ33700332-EDE5CA19-6EC9-41D8-87D6-A8B1016E0B7CQ33725003-7A7C7D8E-C296-43B6-834E-8D72D13794FBQ33749878-0751BA7B-B9D7-442E-ABD4-F37FC44F5C60Q33750608-B06CAF35-DE98-40C9-82FC-04DB4F9002E8Q33755332-7255086D-5579-4AC7-B1CF-F3200CBA2305Q33869816-2308CADC-67D1-4D43-9D07-913B23D2AA7EQ34001251-F7F2B38E-3174-4596-9F77-0C2266450A48Q34172388-A6B54CBF-339F-4C41-8BE9-FD5D4E7E892EQ34461859-09AEA9F8-72CD-4443-A763-E1D101541C4AQ34653798-2324EAEB-D84F-499C-9169-45058460BE76Q34938962-4E95BCF3-52E4-45D1-9FF5-70D8D6FE0DFFQ34987817-D8349607-12CB-436A-A9C5-859F358486D5Q35004854-976D4091-3E93-4FB4-AB25-C57C2E546E20Q35095222-35850ED8-520A-48AD-95A0-1A8DF661C67FQ35133453-27525F10-10D6-4C85-9CC5-5D87D949D254Q35147896-A9B8D99B-AAD2-4F28-BB1D-E17CDF5AD473Q35218922-446E8A6D-BB45-4390-8DF2-44F3126678DBQ35529307-CF31E381-C69E-46CB-875C-D949E38D0098Q35551211-E7164520-D7E3-4235-903F-663748B50135Q35661307-D0D1CFE1-9E64-46BC-BFFE-F95678474F34Q35743851-81CAEAD1-A7FA-4A95-A62A-96344B27DF3AQ35748879-17338C6D-35FF-4E1F-AAED-3B058EE2885AQ35758475-88D1D018-B44C-4019-8D46-4DD21C923827
P2860
Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Impaired collateral vessel dev ...... and therapeutic implications.
@ast
Impaired collateral vessel dev ...... and therapeutic implications.
@en
Impaired collateral vessel dev ...... and therapeutic implications.
@nl
type
label
Impaired collateral vessel dev ...... and therapeutic implications.
@ast
Impaired collateral vessel dev ...... and therapeutic implications.
@en
Impaired collateral vessel dev ...... and therapeutic implications.
@nl
prefLabel
Impaired collateral vessel dev ...... and therapeutic implications.
@ast
Impaired collateral vessel dev ...... and therapeutic implications.
@en
Impaired collateral vessel dev ...... and therapeutic implications.
@nl
P1476
Impaired collateral vessel dev ...... and therapeutic implications.
@en
P2093
Waltenberger J
P304
P356
10.1016/S0008-6363(00)00228-5
P577
2001-02-01T00:00:00Z